Patients with spontaneous remission of high-risk MDS and AML show persistent preleukemic clonal hematopoiesis.

Autor: Grunwald VV; Laboratory for Leukemia Diagnostics, Department of Internal Medicine III, University Hospital, LMU Munich, Munich, Germany., Hentrich M; Department of Internal Medicine, Hematology and Oncology, Red Cross Hospital, Munich, Germany; and., Schiel X; Department of Oncology, Hematology and Palliative Care, Klinikum Harlaching, Munich, Germany., Dufour A; Laboratory for Leukemia Diagnostics, Department of Internal Medicine III, University Hospital, LMU Munich, Munich, Germany., Schneider S; Laboratory for Leukemia Diagnostics, Department of Internal Medicine III, University Hospital, LMU Munich, Munich, Germany., Neusser M; Laboratory for Leukemia Diagnostics, Department of Internal Medicine III, University Hospital, LMU Munich, Munich, Germany., Subklewe M; Laboratory for Leukemia Diagnostics, Department of Internal Medicine III, University Hospital, LMU Munich, Munich, Germany., Fiegl M; Laboratory for Leukemia Diagnostics, Department of Internal Medicine III, University Hospital, LMU Munich, Munich, Germany., Hiddemann W; Laboratory for Leukemia Diagnostics, Department of Internal Medicine III, University Hospital, LMU Munich, Munich, Germany., Spiekermann K; Laboratory for Leukemia Diagnostics, Department of Internal Medicine III, University Hospital, LMU Munich, Munich, Germany., Rothenberg-Thurley M; Laboratory for Leukemia Diagnostics, Department of Internal Medicine III, University Hospital, LMU Munich, Munich, Germany., Metzeler KH; Laboratory for Leukemia Diagnostics, Department of Internal Medicine III, University Hospital, LMU Munich, Munich, Germany.
Jazyk: angličtina
Zdroj: Blood advances [Blood Adv] 2019 Sep 24; Vol. 3 (18), pp. 2696-2699.
DOI: 10.1182/bloodadvances.2019000265
Databáze: MEDLINE